Session » RA – Treatments III: Predictors of Treatment Response (2003–2007)

Date: Monday, November 9, 2020

Time: 4:00PM-4:50PM

Meeting: ACR Convergence 2020

4:00PM-4:50PM: Abstract Number: 2004

Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients

4:00PM-4:50PM: Abstract Number: 2005

Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis

4:00PM-4:50PM: Abstract Number: 2006

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

4:00PM-4:50PM: Abstract Number: 2003

Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach

4:00PM-4:50PM: Abstract Number: 2007

Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].